Methicillin-resistant staphylococcus
aureus (MRSA) infections are caused due to Staphylococcus aureus bacterium
which infects different parts of the body. These infections are difficult to
treat due to high degree of resistance of these pathogens to the most commonly
used antibiotics such as methicillin, amoxicillin, penicillin and oxacillin.
The bacterium infects different parts of the body namely, skin, surgical
wounds, blood streams, lungs, IV or other sites where the tubes such as
catheters enter the body or the urinary tract and cause infection which can be
life threatening.
MRSA infection is known to spread by
casual contact or through contaminated objects called community associated MRSA
(CA MRSA). It may also be acquired in hospitals or health care settings -
healthcare associated MRSA (HA MRSA) which is the most common form of MRSA
infection. Community associated methicillin resistant S. aureus (CA-MRSA)
infections are different from healthcare associated methicillin resistant S.
aureus (HA-MRSA) considering their epidemiology and the characteristics of the
strains which causes the infection. Overuse of antibiotics and use of potent
drugs for less serious infections may also cause development of MRSA. The
symptoms of infection depend on the site of infection and it can be diagnosed
by laboratory testing.
One of the major drivers
contributing to the market growth for MRSA drugs is increase in the prevalence
of MRSA infections. In addition, growth in the government and non-government
awareness programs has also become a key factor in improving the market growth.
However, overcoming the tendency of pathogen for developing resistance to
multi-drugs and increase in competition between the generic market players
could impose a challenge to the market growth.
MRSA can be usually treated by
antibiotics such as bactrim and vancomycin though the pathogen has started
developing resistance for these drugs too owing to its constant adapting power
to newly developed antibiotics. Other options for the treatment of MRSA
infection are generics such as clindamycin and minocycline, and prime
brand-names such as Tygacil, Cubicin, Zyvox, and Synercid. Some of these
antibiotics are only available intravenously. The most effective way of
controlling the spread of MRSA is practicing basic hygiene such as use of
disposable gloves, washing hands before making direct contact with patients as
well as proper wound care.
Geographically, North America leads
this market and is followed by Europe. However, increase in the development of
healthcare infrastructure in emerging economies forecasts growth in demand for
MRSA drugs in Asia-Pacific and other parts of the world. Some of the major
players in this market include Takeda Pharmaceutical Company Limited, Merck
& Co., Inc, AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Cubist Pharmaceuticals,
Inc., ViroPharma, Inc., Forest Laboratories, Inc., and Theravance, Inc.
About Us
MarketResearchReports.Biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs,
our main offerings are syndicated research reports, custom research,
subscription access and consulting services. We serve all sizes and types of
companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948
